LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung
Clinical trial NCT01466660 · COMPLETED
Trial details
- NCT number
- NCT01466660
- Sponsor
- Boehringer Ingelheim
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2011-12-13
- Primary completion
- 2016-04-08
- Enrollment
- 319
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.